



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jim Wells et al. Docket No.: 39750-0002DV1C1
Serial No.: 10/043,833 Group Art Unit: 1639
Filing Date: January 11, 2002 Examiner: Epperson, Jon D.
For: **METHODS FOR RAPIDLY IDENTIFYING SMALL ORGANIC
MOLECULE LIGANDS FOR BINDING TO BIOLOGICAL TARGET
MOLECULES**

TERMINAL DISCLAIMER UNDER 37 CFR § 1.321(c)

Mail Stop: No-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

1. The owner, Sunesis Pharmaceuticals, Inc., having a principal place of business at 341 Oyster Point Boulevard, South San Francisco, CA 94080, represents that it is the owner of the entire right, title and interest in the invention disclosed and claimed in the above-identified patent application. Sunesis Pharmaceuticals, Inc. is also the owner of the entire right, title and interest in the invention disclosed in U.S. Patent Publication Nos. 2002/0022233 and 2002/0081621.

Sunesis Pharmaceuticals, Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of any of U.S. Patents issuing from U.S. Patent Publication No. 2002/0022233 or 2002/0081621. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the U.S. Patents issuing from U.S. Patent Publication Nos. 2002/0022233 and 2002/0081621 are commonly owned. This agreement runs with any patent granted on the instant application, and is binding upon the grantee, its successors or assigns.

10/30/2003 BABRAHA1 00000103 081641 10043833

02 FC:2814

55.00 DA

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, or in the event that it later is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole, or terminally disclaimed under 37 C.F.R. 1.321; has all claims canceled by a re-examination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

2. For submission on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.


3. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

4. The undersigned is an attorney of record.

5. The Commissioner is authorized to charge any fees, including any fees for extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No.: 39750-0002DV1C1).

Respectfully submitted,

Date: October 27, 2003


Ginger R. Dreger
Reg. No. 33,055

HELLER EHRMAN WHITE & McAULIFFE LLP

Customer No. 25213

275 Middlefield Road

Menlo Park, California 94025

Telephone: (650) 324-7000

Facsimile: (650) 324-0638